<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03351101</url>
  </required_header>
  <id_info>
    <org_study_id>ROC2-17-014</org_study_id>
    <nct_id>NCT03351101</nct_id>
  </id_info>
  <brief_title>Clinical Study of Approved Contact Lenses</brief_title>
  <official_title>Clinical Study of Approved Contact Lenses</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bausch &amp; Lomb Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bausch &amp; Lomb Incorporated</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of Johnson &amp; Johnson Acuvue Vita (senofilcon C) soft contact lenses to the Bausch&#xD;
      + Lomb Ultra (samfilcon A) soft contact lenses&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      to compare the performance of currently marketed Johnson &amp; Johnson Acuvue Vita (senofilcon C)&#xD;
      soft contact lenses to the currently marketed Bausch + Lomb Ultra (samfilcon A) soft contact&#xD;
      lenses among adapted wearers of Acuvue Oasys soft contact lenses.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 23, 2017</start_date>
  <completion_date type="Actual">December 8, 2017</completion_date>
  <primary_completion_date type="Actual">November 10, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>randomized, bilateral, d o u b l e - masked, 1-month study with two parallel groups</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>End of Day Comfort</measure>
    <time_frame>1 month</time_frame>
    <description>The 100 point , take home questionnaire evaluated performance of the lenses based on subject responses. Possible scores were 0-100. Higher scores indicated greater comfort.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Vision</measure>
    <time_frame>1 month</time_frame>
    <description>The 100 point , take home questionnaire evaluated performance of the lenses based on subject responses. Possible scores were 0-100. Higher scores indicated better overall vision.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">271</enrollment>
  <condition>Myopia</condition>
  <arm_group>
    <arm_group_label>Senofilcon C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Senofilcon C Contact Lens</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Samfilcon A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Samfilcon A Contact Lens</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Senofilcon C</intervention_name>
    <description>Senofilcon C Contact Lens</description>
    <arm_group_label>Senofilcon C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Samfilcon A</intervention_name>
    <description>Samfilcon A Contact Lens</description>
    <arm_group_label>Samfilcon A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects must be between the ages of 18 and 40 years old, inclusive, on the date the&#xD;
             Informed Consent Form (ICF) is signed and have the capacity to provide voluntary&#xD;
             informed consent.&#xD;
&#xD;
          2. Subjects must be able to read, understand and provide written informed consent on the&#xD;
             Institutional Review Board (IRB)/Ethics Committee (EC) approved ICF and provide&#xD;
             authorization as appropriate for local privacy regulations.&#xD;
&#xD;
          3. Subjects must be willing and able to comply with all treatment and follow-up/study&#xD;
             procedures.&#xD;
&#xD;
          4. Subjects must be correctable through spherocylindrical refraction to 32 letters (0.3&#xD;
             logMAR) or better (distance, high contrast) in each eye.&#xD;
&#xD;
          5. Subjects must have clear central corneas and be free of any anterior segment&#xD;
             disorders.&#xD;
&#xD;
          6. Subjects must be myopic and require contact lens sphere power correction from -0.50&#xD;
             diopter (D) to -6.00 D (considering vertex distance adjustments in both eyes).&#xD;
&#xD;
          7. Subjects must be habitual wearers of Johnson &amp; Johnson Acuvue Oasys single vision&#xD;
             spherical soft contact lenses in each eye.&#xD;
&#xD;
          8. Subjects must use a contact lens care regimen on a routine basis.&#xD;
&#xD;
          9. Subjects must agree to wear their study lenses on a daily wear basis for the duration&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects participating in any drug or device clinical investigation within two weeks&#xD;
             prior to entry into this study and/or during the period of study participation&#xD;
&#xD;
          2. Subjects who are women of childbearing potential (those who are not surgically&#xD;
             sterilized or postmenopausal) are excluded from participation in the investigation if&#xD;
             they meet any one of the following conditions:&#xD;
&#xD;
               -  she is currently pregnant&#xD;
&#xD;
               -  she plans to become pregnant during the study&#xD;
&#xD;
               -  she is breastfeeding&#xD;
&#xD;
          3. Subjects with any systemic disease currently affecting ocular health or which in the&#xD;
             Investigator's opinion may have an effect on ocular health during the course of the&#xD;
             study.&#xD;
&#xD;
          4. Subjects using any systemic or topical medications that will, in the Investigator's&#xD;
             opinion, affect ocular physiology or lens performance.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>valeant Site 02</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valeant Site 03</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valeant Site 04</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valeant Site 06</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valeant Site 01</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32812</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valeant Site 05</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valeant Site 07</name>
      <address>
        <city>Pittsburg</city>
        <state>Kansas</state>
        <zip>66762</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valeant Site 08</name>
      <address>
        <city>Warrensburg</city>
        <state>Missouri</state>
        <zip>64093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valeant Site 09</name>
      <address>
        <city>Vestal</city>
        <state>New York</state>
        <zip>13850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valeant Site 10</name>
      <address>
        <city>Powell</city>
        <state>Ohio</state>
        <zip>43065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valeant Site 11</name>
      <address>
        <city>New Berlin</city>
        <state>Wisconsin</state>
        <zip>53151</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>November 9, 2017</study_first_submitted>
  <study_first_submitted_qc>November 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 22, 2017</study_first_posted>
  <results_first_submitted>August 27, 2020</results_first_submitted>
  <results_first_submitted_qc>September 14, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 16, 2020</results_first_posted>
  <last_update_submitted>January 6, 2021</last_update_submitted>
  <last_update_submitted_qc>January 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myopia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 29, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/01/NCT03351101/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>There were 271 participants enrolled, with 136 Senofilcon C participants dispensed lenses and 132 Samfilcon A participants dispensed lenses (268 participants total).</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Senofilcon C</title>
          <description>Senofilcon C Contact Lens&#xD;
Senofilcon C: Senofilcon C Contact Lens</description>
        </group>
        <group group_id="P2">
          <title>Samfilcon A</title>
          <description>Samfilcon A Contact Lens&#xD;
Samfilcon A: Samfilcon A Contact Lens</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="136"/>
                <participants group_id="P2" count="132"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="135"/>
                <participants group_id="P2" count="129"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All participants that completed all study visits without a major protocol deviation.</population>
      <group_list>
        <group group_id="B1">
          <title>Senofilcon C</title>
          <description>Senofilcon C Contact Lens&#xD;
Senofilcon C: Senofilcon C Contact Lens</description>
        </group>
        <group group_id="B2">
          <title>Samfilcon A</title>
          <description>Samfilcon A Contact Lens&#xD;
Samfilcon A: Samfilcon A Contact Lens</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="115"/>
            <count group_id="B2" value="106"/>
            <count group_id="B3" value="221"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.5" spread="5.62"/>
                    <measurement group_id="B2" value="30.4" spread="5.72"/>
                    <measurement group_id="B3" value="30.45" spread="5.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                    <measurement group_id="B2" value="68"/>
                    <measurement group_id="B3" value="139"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="98"/>
                    <measurement group_id="B2" value="90"/>
                    <measurement group_id="B3" value="188"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>End of Day Comfort</title>
        <description>The 100 point , take home questionnaire evaluated performance of the lenses based on subject responses. Possible scores were 0-100. Higher scores indicated greater comfort.</description>
        <time_frame>1 month</time_frame>
        <population>All participants that completed all study visits without a major protocol deviation.</population>
        <group_list>
          <group group_id="O1">
            <title>Senofilcon C</title>
            <description>Senofilcon C Contact Lens&#xD;
Senofilcon C: Senofilcon C Contact Lens</description>
          </group>
          <group group_id="O2">
            <title>Samfilcon A</title>
            <description>Samfilcon A Contact Lens&#xD;
Samfilcon A: Samfilcon A Contact Lens</description>
          </group>
        </group_list>
        <measure>
          <title>End of Day Comfort</title>
          <description>The 100 point , take home questionnaire evaluated performance of the lenses based on subject responses. Possible scores were 0-100. Higher scores indicated greater comfort.</description>
          <population>All participants that completed all study visits without a major protocol deviation.</population>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
                <count group_id="O2" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80" spread="18.15"/>
                    <measurement group_id="O2" value="80" spread="20.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Overall Vision</title>
        <description>The 100 point , take home questionnaire evaluated performance of the lenses based on subject responses. Possible scores were 0-100. Higher scores indicated better overall vision.</description>
        <time_frame>1 month</time_frame>
        <population>All participants that completed all study visits without a major protocol deviation.</population>
        <group_list>
          <group group_id="O1">
            <title>Senofilcon C</title>
            <description>Senofilcon C Contact Lens&#xD;
Senofilcon C: Senofilcon C Contact Lens</description>
          </group>
          <group group_id="O2">
            <title>Samfilcon A</title>
            <description>Samfilcon A Contact Lens&#xD;
Samfilcon A: Samfilcon A Contact Lens</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Vision</title>
          <description>The 100 point , take home questionnaire evaluated performance of the lenses based on subject responses. Possible scores were 0-100. Higher scores indicated better overall vision.</description>
          <population>All participants that completed all study visits without a major protocol deviation.</population>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
                <count group_id="O2" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95" spread="9.68"/>
                    <measurement group_id="O2" value="95" spread="12.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 month</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Senofilcon C</title>
          <description>Senofilcon C Contact Lens&#xD;
Senofilcon C: Senofilcon C Contact Lens</description>
        </group>
        <group group_id="E2">
          <title>Samfilcon A</title>
          <description>Samfilcon A Contact Lens&#xD;
Samfilcon A: Samfilcon A Contact Lens</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Corneal infiltrates</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Contact sponsor directly for details.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Bausch Health</organization>
      <phone>+1 (585) 338-6399</phone>
      <email>Robert.Steffen@bausch.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

